Cellular reactive oxygen species-generating machinery (ROS-generating machinery)

The cellular reactive oxygen species (ROS)-generating machinery is a collective term for the diverse enzymatic and organelle-based systems that produce superoxide, hydrogen peroxide, and other reactive oxygen species. The primary components include the NADPH oxidase (NOX) family, which are the only enzymes dedicated solely to ROS production, and the mitochondrial electron transport chain, where ROS are generated as byproducts of oxidative phosphorylation (Bedard & Krause, 2007; Murphy, 2009). Other contributors include xanthine oxidase, cytochrome P450 enzymes, and peroxisomal oxidases. This machinery plays a dual role in biology: at low levels, ROS act as critical signaling molecules for cell proliferation and survival, while at high levels, they cause oxidative damage to DNA, proteins, and lipids. Dysregulation of this machinery is implicated in various diseases, including cancer, neurodegeneration, and cardiovascular disorders, where excessive ROS production leads to chronic inflammation and tissue damage. In therapeutic contexts, this machinery is targeted by pro-oxidant drugs like CuNG and MnNG to selectively kill cancer cells by inducing lethal oxidative stress, or by inhibitors like setanaxib to treat chronic inflammatory and fibrotic conditions (Mondal et al., 2007; Lambeth & Neish, 2014). Drugs interacting with this machinery often modulate the redox state of the cell by either stimulating ROS production to trigger apoptosis or inhibiting specific enzymes to restore redox homeostasis.

Other names

ROS-generating systemCellular ROS sourcesPro-oxidant machineryNADPH oxidase complexMitochondrial ROS machinery

Drugs targeting the cellular ROS-generating machinery act either as pro-oxidants or antioxidants. Pro-oxidant compounds, such as metal-glycinate complexes (CuNG, MnNG), interact with the machinery to induce a surge in ROS production, overwhelming the antioxidant capacity of cancer cells and triggering apoptosis (Mondal et al., 2007). Conversely, inhibitors like Setanaxib or Apocynin suppress the activity of specific components like NADPH oxidases to reduce pathological oxidative stress in inflammatory or fibrotic diseases (Bedard & Krause, 2007).